CollPlant Biotechnologies Ltd: Business Overview, Financials & Competitive Analysis
CollPlant Biotechnologies Ltd scores 4/10 on the AskCyborg Cyborg Score (Challenged). Early-stage biotech with differentiated platform technology but challenged by capital constraints and commercialization execution. CollPlant faces significant headwinds: micro-cap valuation ($25M market cap), depressed stock price, low liquidity, and negative sentiment in early June 2026. Limited recent revenue data and emerging technology face regulatory and commercialization risks inherent to.
What is CollPlant Biotechnologies Ltd's industry? CollPlant Biotechnologies Ltd (collplant.com) operates in Regenerative Medicine & Bioprinting. AskCyborg classifies CollPlant Biotechnologies Ltd under Regenerative Medicine & Bioprinting in its company registry.
CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. The technology is based on plant-derived production of recombinant hum...
Cyborg Score thesis
Early-stage biotech with differentiated platform technology but challenged by capital constraints and commercialization...
Read the full analyst-debate transcript →Get the Latest CollPlant Biotechnologies Ltd Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCollPlant Biotechnologies Ltd Overview
Pro stress-test →CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. The technology is based on plant-derived production of recombinant human collagen type I (rhCollagen), enabling proprietary bioinks and regenerative products.
Strategic Profile
Pro stress-test →The company offers regenerative dermal and soft tissue fillers, 3D-bioprinted regenerative breast implants, and wound care products including VergenixSTR and VergenixFG. The platform leverages plant-based collagen production, creating a differentiated technology moat in the regenerative medicine space.
Competitive Landscape
Pro stress-test →CollPlant competes in regenerative medicine and aesthetic medicine. Direct competitors include other biotech firms developing tissue engineering, bioprinting, and collagen-based therapeutics. The broader competitive set includes Envisiontec (bioprinting), Organogenesis (regenerative medicine), and traditional aesthetic product manufacturers.
Industry Context
CollPlant Biotechnologies Ltd operates in Regenerative Medicine & Bioprinting.
Key facts
Founded: 2004 · Headquarters: Rehovot, Israel · Employees: N/A · Revenue: N/A · Market cap: $25M